Historical record - last NADAC effective date: 2/21/2013
Product Information
ANTARA 43 MG CAPSULE is a brand product labeled by Lupin Pharmaceuticals Inc., priced at $2.1404 per EA under NDC 27437010906. Its NADAC has been published 3 times since Nov 28, 2013.
FDA first approved this application on Nov 30, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the FENOFIBRATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
43 mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
27437010906
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
2/21/2013
Active Ingredients
FENOFIBRATEApproval Type
New Drug (NDA)
FDA Application
NDA021695FDA Approved
11/30/2004
TE Code
AB
On Market Since
9/25/2009
Pharmacological Classes
Price Statistics
The NADAC for ANTARA 43 MG CAPSULE has been published 3 times since Nov 28, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.1404 per EA |
|---|---|
| All-time high | $2.1404 (Dec 11, 2013) |
| All-time low | $2.1404 (Nov 28, 2013) |
| Median price | $2.1404 |
| Average price | $2.1404 |
| Largest weekly change | 0.0% (Dec 5, 2013) |
| Weeks tracked | 3 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Dec 11, 2013 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the FENOFIBRATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
FENOFIBRATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ANTARA 43 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ANTARA 43 MG CAPSULE, manufactured by Lupin Pharmaceuticals Inc., is $2.1404 per EA (NDC 27437010906), effective Dec 11, 2013.
How has the price of ANTARA 43 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ANTARA 43 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 3 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ANTARA 43 MG CAPSULE?
Since Nov 28, 2013, the NADAC for ANTARA 43 MG CAPSULE has ranged from a low of $2.1404 (Nov 28, 2013) to a high of $2.1404 (Dec 11, 2013), with a median of $2.1404 per EA.
Are there cheaper alternatives to ANTARA 43 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of ANTARA 43 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ANTARA 43 MG CAPSULE?
ANTARA 43 MG CAPSULE (NDC 27437010906) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a brand product.